Numéro tarifaire 3002490000 80 - autres

Estimer le coût d’importation pour 300249

Simple estimation. La valeur en douane est le prix incluant le transport et l’assurance jusqu’à la frontière de l’UE. Les accises, autres redevances et droits antidumping propres à un producteur ne sont pas inclus. Les taux préférentiels exigent une preuve d’origine valable. Groupes de pays et exclusions : TARIC, au novembre 2026.

Mesures à l’exportation pour 3002490000

Ce qui s’applique quand ces marchandises quittent l’UE : contrôles à l’exportation, autorisations (biens à double usage et autres), interdictions par destination et unité supplémentaire de la déclaration d’exportation.

Contrôles et documents 11

	Destination	Début	Droit / Impôt	Base légale Type de mesure
KP	North Korea (Democratic People’s Republic of Korea) KP	01-01-2022	Document requis interdit sans document Détails	Régulation1509/17 Export control on restricted goods and technologies 717
SY	Syria SY	01-01-2022	Document requis interdit sans document Détails	Régulation0509/12 Export control on restricted goods and technologies 717
IR	Iran, Islamic Republic of IR	01-01-2022	Document requis interdit sans document Détails	Régulation0267/12 Restriction on export 476
1008	All third countries 1008	15-11-2025	Document requis interdit sans document Détails	Régulation2003/25 Export authorization (Dual use) 478
ZW	Zimbabwe ZW	19-02-2026	Document requis interdit sans document Détails	Régulation0384/26 Export control 737
1008	All third countries 1008	20-05-2023	Document requis interdit sans document Détails	Régulation0966/23 Export control - CITES 715
BY	Belarus BY	20-07-2025	Document requis interdit sans document Détails	Régulation0765/06 Export control 737
RU	Russian Federation RU	20-07-2025	Document requis interdit sans document Détails	Régulation0833/14 Import/export restriction - Common Military List (CML) goods 738
RU	Russian Federation RU	24-06-2023	Document requis interdit sans document Détails	Régulation0833/14 Export control 767
BY	Belarus BY	25-02-2025	Document requis interdit sans document Détails	Régulation0765/06 Export control 767
CD	Congo, Democratic Republic of CD	28-10-2026	Document requis interdit sans document Détails	Régulation1183/05 Export control 737

Historique

Règles d’origine préférentielles pour 3002490000

Ce que la marchandise doit remplir pour être originaire d’un pays partenaire et bénéficier du droit préférentiel, par accord. Texte des accords en anglais.

• EU-Egypt Association Agreement · Égypte

  EU-Lebanon Association Agreement · Liban

  EU-Morocco Association Agreement · Maroc

  Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products:

  – Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  – Other

  – – Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  – – Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  – – Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  – – Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  – – Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

• Generalised Scheme of Preferences (GSP, GSP+, EBA) · Arménie, Îles Salomon, Inde, Kenya, Pakistan, Samoa, Syrie, Viêt Nam

  EU-Singapore FTA · Singapour

  Pharmaceutical products / or: Manufacture from materials of any heading

• Autonomous Trade Preferences (Western Balkans) · Kosovo

  Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products:

  - Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  - Other:

  - - Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  - - Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  - - Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  - - Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  - - Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

• EU-Canada CETA · Canada

  A change from within any one of these subheadings or any other subheading.

• EU-Chile Association Agreement · Chili

  Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: — Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — Other — — Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — — Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — — Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — — Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product — — Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

• EU-Colombia/Peru/Ecuador Trade Agreement · Colombie, Équateur, Pérou

  Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products:

  Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product

  Other:

  Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product

  Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product

  Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product

  Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product

  Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 per cent of the ex-works price of the product

• EU-Algeria Association Agreement · Algérie

  Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of microorganisms (excluding yeasts) and similar products:

  – Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  – Other

  – – Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  – – Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  – – Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  – – Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

  – – Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

• EPA CARIFORUM

  Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: – Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product – Other: – – human blood / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product – – animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product – – blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product – – haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product – – other / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product

• EU Market Access Regulation (EPA) · Cameroun, Côte d’Ivoire, Ghana, Kenya

  Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products:

  – Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packing's for retail sale / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product

  – Other:

  – – human blood / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product

  – – animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product

  – – blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product

  – – haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product

  – – other / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product

• EU-Jordan Association Agreement · Jordanie

  Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: - Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - Other - - Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - - Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - - Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - - Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product - - Other / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

• EU-Japan EPA · Japon

  CTSH; A chemical reaction, purification, mixing and blending, production of standard materials, a change in particle size, isomer separation or biotechnological processing is undergone; MaxNOM 50 % (EXW); or RVC 55 % (FOB).

• EU-Korea FTA · Corée du Sud

  Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products. / or: Manufacture from materials of any heading

• EU-Central America Association Agreement

  Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products,whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products / or: Manufacture from materials of any heading

• EU-Mexico Global Agreement · Mexique

  Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: — Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product — Other: — — Human blood / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product — — Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product — — Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product — — Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product — — Other / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20 % of the ex-works price of the product

• EU-Palestine Interim Association Agreement · Palestine

  Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: - Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product - Other: -- human blood / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product -- animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product -- blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product -- haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product -- other / or: Manufacture from materials of any heading, including other materials of heading No 3002. The materials of this description may also be used, provided their value does not exceed 20% of the ex-works price of the product

• EU-Tunisia Association Agreement · Tunisie

  Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: Products consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses or unmixed products for these uses, put up in measured doses or in forms or packings for retail sale / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Human blood / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Animal blood prepared for therapeutic or prophylactic uses / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Blood fractions other than antisera, haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Haemoglobin, blood globulins and serum globulins / or: Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product Manufacture from materials of any heading, including other materials of heading 3002. However, materials of the same description as the product may be used, provided that their total value does not exceed 20 % of the ex-works price of the product

• EU-Viet Nam FTA · Viêt Nam

  Pharmaceutical products. / or: Manufacture from materials of any heading.

Source : Commission européenne, Access2Markets (CC BY 4.0, abrégé). Seul le texte de l’accord fait foi. Access2Markets

Notes légales et notes explicatives pour 3002490000

Sources : nomenclature combinée 2026, annexe I du règlement (CEE) nº 2658/87 (CELEX 32025R1926), et notes explicatives de la nomenclature combinée (CELEX 02019XC0329(02)-20260213). Les notes de section et de chapitre ont force juridique ; les notes explicatives sont une aide à l’interprétation. EUR-Lex

Renseignements tarifaires du Royaume-Uni pour 3002490000

Décisions de HM Revenue & Customs pour des marchandises dont le code britannique commence comme ce code de l’UE. Le tarif britannique diffère de celui de l’UE : ces décisions ne sont qu’une indication pour l’UE.

• UK 3002490020 Valable du 30 juil. 2026 au 29 juil. 2029 · Décision 600015835 sur GOV.UK

  Bespoke fungal cultures embedded on pellet 'scaffolds'. The scaffolds are soaked in nutrient media to encourage fungal growth. The fungi used are ectomycorrhizal, meaning they form symbiotic relationships with tree roots, improving the tree's access to water and nutrients from the soil. These pellets are used when planting trees to improve their growth rate and survivability. The species used in this pellet is dependent on which are local to area in which trees are being planted. These belong to a specific list of genera. The pellets are packaged in heat sealed, filtered polypropylene bags of 200, and further into bulk boxes.

  Justification

  Classification has been determined in accordance with the following: For the purposes of determining the commodity codes within which goods most appropriately fall, reg 3 (1) of The Customs Tariff (Establishment) (EU Exit) Regulations 2020 sets out that the rules of interpretation contained in the following have effect – a. Part Two (Goods Classification Table Rules of Interpretation) of the Tariff of the United Kingdom (Reg 3(1)(a)); and b. Notes to a section or chapter of the Goods Classification Table (Reg 3(1)(b)). General interpretative rules (GIR)s: GIR 1 has been used to classify this product to Heading 3002 - Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified GIR 5B - has been used to determine the type of packaging. GIR 6 has been used to classify this product to sub-heading level 300249 - Vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar …

• UK 3002490020 Valable du 8 sept. 2026 au 7 sept. 2029 · Décision 600016294 sur GOV.UK

  A powdered silage additive containing lactic acid bacteria to control fermentation, a stabilising strain to enhance aerobic stability, enzymes to improve fibre digestibility, and microbial stimulants to promote rapid activation when dissolved in water. Produced by fermentation and product is packaged in a 150 g plastic bottle.

  Justification

  Classification has been determined in accordance with the following: For the purposes of determining the commodity codes within which goods most appropriately fall, reg 3 (1) of The Customs Tariff (Establishment) (EU Exit) Regulations 2020 sets out that the rules of interpretation contained in the following have effect – a. Part Two (Goods Classification Table Rules of Interpretation) of the Tariff of the United Kingdom (Reg 3(1)(a)); and b. Notes to a section or chapter of the Goods Classification Table (Reg 3(1)(b)) General Interpretative Rules (GIR)s: GIR 1 Has been used to classify this product by the terms of heading 3002 - Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified. GIR 5B Has been used identify the type of packaging: 150g plastic bottle. GIR 6 Has been used to classify this product by the terms of heading 300249 - Vaccines, toxins, cultures of micro-organisms …

• UK 3002490020 Valable du 8 sept. 2026 au 7 sept. 2029 · Décision 600016295 sur GOV.UK

  A silage additive in powder form containing lactic acid bacteria that control forage fermentation, including a specific stabilising strain that enhances aerobic stability. The product is produced by fermentation. Packaged in a 400 g plastic bottle.

  Justification

  Classification has been determined in accordance with the following: For the purposes of determining the commodity codes within which goods most appropriately fall, reg 3 (1) of The Customs Tariff (Establishment) (EU Exit) Regulations 2020 sets out that the rules of interpretation contained in the following have effect – a. Part Two (Goods Classification Table Rules of Interpretation) of the Tariff of the United Kingdom (Reg 3(1)(a)); and b. Notes to a section or chapter of the Goods Classification Table (Reg 3(1)(b)) General Interpretative Rules (GIR)s: GIR 1 Has been used to classify this product by the terms of heading 3002 - Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified. GIR 5B Has been used identify the type of packaging: 400g plastic bottle. GIR 6 Has been used to classify this product by the terms of heading 300249 - Vaccines, toxins, cultures of micro-organisms …

Source : HM Revenue & Customs, Advance Tariff Rulings. Contient des informations du secteur public sous licence Open Government Licence v3.0.

Restrictions et signalements pour 300249

• Biens à double usage Règlement (UE) 2021/821, Annexe I 30024900

  Ne couvre qu’une partie des marchandises sous ce code (l’acte cite 30024900).

  Peut être à double usage ; vérifier l'entrée 1C351, 1C353, 1C354 de l'annexe I (table de correspondance non contraignante)

  Lire l’acte sur EUR-Lex

À titre indicatif. Vérifiez l’acte avant de vous fier à un signalement ; les seuils, dérogations et exceptions ne sont pas tous indiqués. Le tableau des biens à double usage relie les codes aux entrées de la liste de contrôle et n’est pas contraignant.

Commerce de l’UE en 2025 pour 300249

Importations extra-UE

1,5 Md €

5 419 t

Exportations extra-UE

6,9 Md €

Principaux pays d’origine selon la valeur importée

1. États-Unis 888,6 M €
2. Royaume-Uni 316,5 M €
3. Singapour 82,5 M €
4. Suisse 47,4 M €
5. Argentine 37,6 M €

Codes NC8 sous ce code : 1. Source : Eurostat, Comext, CC BY 4.0, traité par hscode.info. Le commerce confidentiel n’est pas attribué aux codes.

Changement du SH 2028

D’après les tables de correspondance de l’OMD du SH 2022 au SH 2028, à titre indicatif. L’UE fixe elle-même ses codes NC pour 2028.

Modifications tarifaires pour 300249 depuis 2016

• déc. 2024 3002490080 Code supprimé
• déc. 2024 2 codes Code créé
• janv. 2022 4 codes Code créé

Comparaison mensuelle des extractions TARIC de la Commission européenne. Prix d’entrée saisonniers exclus.

Droit d’importation au Royaume-Uni pour 300249

• 0%

Droits de pays tiers de tous les codes britanniques sous cette sous-position du SH. Source : UK Department for Business and Trade, au 2 nov. 2026. Le tarif britannique diffère du tarif de l’UE.

TVA à l’importation dans l’UE

• Allemagne 19 %
• Autriche 20 %
• Belgique 21 %
• Bulgarie 20 %
• Chypre 19 % éventuellement 5 %
• Croatie 25 %
• Danemark 25 %
• Espagne 21 %
• Estonie 24 % éventuellement 9 %
• Finlande 25,5 %
• France 20 %
• Grèce 24 % éventuellement 6 %, 13 %
• Hongrie 27 %
• Irlande 23 %
• Italie 22 %
• Lettonie 21 % éventuellement 12 %
• Lituanie 21 % éventuellement 5 %
• Luxembourg 17 %
• Malte 18 % éventuellement 5 %
• Pays-Bas 21 %
• Pologne 23 %
• Portugal 23 %
• Roumanie 21 % éventuellement 11 %
• Slovaquie 23 % éventuellement 5 %
• Slovénie 22 % éventuellement 9,5 %
• Suède 25 %
• Tchéquie 21 % éventuellement 12 %

Taux normal par État membre, sur la valeur en douane, les droits et le transport jusqu’à destination. Les taux réduits dépendent souvent de l’usage ou de l’acheteur et ne s’appliquent que si le pays les prévoit pour ces marchandises. Source : Commission européenne, Taxes in Europe Database, au 2 nov. 2026.

Règles d’origine

Informations

Structure du HS-Code

Arborescence HS-Code